Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DUPIXENT Portal

Watch the Sanofi-sponsored BAD Q&A webinar

DUPIXENT was studied in adult patients with moderate-to-severe AD who were inadequately controlled by topical treatments or ciclosporin1

 

Discover the emerging science in AD from experts in the field.

The first targeted immunomodulator for patients aged 12 years and older with uncontrolled moderate-to-severe AD1,2

Resources

Find out what additional resources are available to download to provide you with further information about DUPIXENT and support you in treating your patients with AD.

DUPIXENT (dupilumab) is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years or older, who are candidates for systemic therapy1

Type 2 inflammation contributes to clinical disease features of AD2-4

Real-world evidence (RWE) studied in a UK tertiary care setting5

>90,000

patients

aged 12 years or older with moderate-to-severe AD have been prescribed DUPIXENT in the U.S.A and Europe as of December 20196

251 adolescent patients with moderate-to-severe AD that were inadequately controlled with topical treatments, participated in a study (AD-1526) to investigate the efficacy of DUPIXENT as a monotherapy for up to 16 weeks1

LATEST NEWS & EVENTS

 

Type 2 Inflammation

IL-4 and IL-13 are key drivers of Type 2 inflammation2

RWE efficacy

Efficacy and safety was reviewed in RWE studies5

DUPIXENT Portal

Gain access to watch past webinars, videos and narrated lectures on DUPIXENT

Expert hub

Listen to experts in the field of Dermatology

Targeted therapy towards IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation1,2

Safety has been investigated in patients for up to 52 weeks in adolescents and 3 years in adults1,9,10

Improvements in lesion extent and severity compared to placebo at 16 weeks in all populations and sustained in adults at 52 weeks1,7-8

DUPIXENT can be self-administered by subcutaneous injection by the pre-filled syringe or pre-filled pen.1

AD, atopic dermatitis; IL, interleukin; RWE, real-world evidence.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: January 2021.
  2. Gandhi NA, et al. Nature Rev Drug Disc. 2016; 15: 35–50.
  3. Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
  4. Biedermann T, et al. Front Immunol. 2015;6:353.
  5. Kreeshan, F.C, et al. Dermatol Ther. 2020. doi.org/10.1007/s13555-020-00469-6.
  6. Sanofi Data on File. MAT-IE-2000837 (v1.0).
  7. Simpson EL, et al. JAMA Dermatol. 2020;156(1):44–56.
  8. Blauvelt A, et al. Lancet. 2017;389(10086):2287–2303.
  9. Thaçi D, et al. Favorable Safety and Sustained Efficacy With Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis up to 3 Years (LIBERTY AD OLE) presented at the 20th Annual Las Vegas Dermatology Seminar, Nevada, USA, November 7–9 2019.
  10. Cork MJ, et al. Br J Dermatol. 2020;182(1):85–96.